Animal Plasma Selection & Handling
Evaluate species, donor variability, anticoagulant, pooling, storage, freeze–thaw history and relevant protein characteristics. Sample availability and compatibility are assessed before assay qualification.
BioVenic designs species-specific plasma protein binding assays for veterinary pharmacology and preclinical ADME research. We tailor equilibrium dialysis or ultrafiltration workflows, plasma matrix selection, compound recovery controls and concentration-dependent measurements to deliver interpretable fraction-unbound data for animal PK study planning.
Total plasma concentrations do not necessarily represent the drug available for distribution and target engagement. Protein binding can differ with animal species, matrix composition and compound concentration, complicating PK/PD interpretation when a result from one model is applied to another.
BioVenic develops animal plasma protein binding workflows around the intended veterinary candidate, selected species and analytical readout. The goal is robust, clearly qualified unbound-fraction estimates—not a one-size-fits-all percentage.
Assay development begins with a compound- and matrix-specific feasibility question. Our proposed scope includes method selection, pilot conditions, analytical quantitation and defined acceptance criteria. Studies can focus on a single veterinary species or a structured comparison across preclinical species.
Evaluate species, donor variability, anticoagulant, pooling, storage, freeze–thaw history and relevant protein characteristics. Sample availability and compatibility are assessed before assay qualification.
Screen device and membrane conditions, plasma–buffer ratios, incubation temperature and equilibration time. Confirm free-drug transfer while evaluating membrane adsorption, matrix stability and volume shift.
Select an appropriate filter cutoff and centrifugation conditions; assess recovery, protein breakthrough and device adsorption. Choose ultrafiltration where justified by the analyte and study design.
Develop a matrix-appropriate LC–MS/MS or otherwise suitable assay, with calibration and quality controls matched to plasma and protein-free fractions when needed.
Assess nonspecific binding, analyte loss, matrix effects, concentration changes, separation integrity and replicate performance. Flag results that cannot be interpreted reliably.
Measure unbound fractions across selected concentrations to examine potential binding saturation or nonlinearity, subject to solubility and analytical sensitivity constraints.
Where disease-related protein changes, unusual species matrices or highly bound analytes are relevant, additional pilot experiments can guide whether the original assay setup remains suitable. Method validation depth is agreed for the intended research application rather than assumed to be regulatory-grade.
Method choice depends on stability, nonspecific binding, plasma availability and required assay sensitivity. Rapid equilibrium dialysis is commonly favored when equilibrium and acceptable recovery can be demonstrated; ultrafiltration may be practical for particular unstable or time-sensitive analytes.
Both approaches require explicit controls. Agreement between methods cannot be assumed for every compound.
| Decision point | Equilibrium dialysis | Ultrafiltration |
|---|---|---|
| Principle | Passive diffusion across a semipermeable membrane | Physical separation of filtrate from plasma proteins |
| Typical fit | Stable compounds that reach equilibrium | Time-sensitive compounds after filter compatibility checks |
| Critical artifact | Membrane/device adsorption; incomplete equilibrium | Filter adsorption; protein leakage or concentration shift |
| Feasibility evidence | Time-to-equilibrium, recovery, stability, volume balance | Filtrate recovery, membrane integrity, centrifugal conditions |
| Primary output | Fraction unbound from paired plasma/buffer measurements | Fraction unbound from plasma/filtrate measurements |
The reporting package is designed to support traceable species comparisons and the next PK or toxicology decision, with assay limitations reported alongside the values.
Align species, plasma matrix, candidate properties and anticipated total exposure with research decisions.
Assess dialysis or filtration feasibility, analyte stability, device binding and analytical sensitivity.
Analyze controls and replicate concentration levels across approved animal plasma matrices.
Summarize percent bound, fraction unbound, species variability and any interpretation constraints.
Results are most useful when they retain the matrix, conditions and QC evidence needed to interpret them.
Calculation convention: fu = Cunbound / Ctotal; % bound = (1 − fu) × 100, where concentrations are comparable and appropriately corrected for the method.
The figure shows a published scatter-plot comparison of plasma protein binding values for antibiotics in humans and several animal species. The reported patterns reveal that interspecies relationships can differ by drug and study species; the review identified differences for canine and murine comparisons in its compiled datasets, while sample counts and compound selection limit generalization.
The review also evaluates equilibrium dialysis and ultrafiltration as methods for separating bound and unbound drug fractions. These principles support a species-first veterinary ADME workflow: select a relevant plasma matrix, assess separation artifacts and measure fraction unbound under controlled conditions. BioVenic can tailor assay development and companion PK-related research support to those needs; the literature is not a validation of BioVenic's own assays.

Research-focused workflows built around analyte behavior and the matrix actually used in veterinary PK studies.
Matrix and study conditions tailored to veterinary species, candidate and intended endpoint.
Dialysis or filtration selected using feasibility evidence and analyte-specific limitations.
Recovery, stability and adsorption controls documented alongside binding estimates.
Traceable unbound-fraction results and limitations for preclinical PK interpretation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.